Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose Inc (OPTN) is a specialty pharmaceutical innovator focused on chronic sinusitis treatments through its patented Exhalation Delivery System. This page provides investors and healthcare professionals with essential updates on regulatory developments, clinical research, and corporate milestones.
Track key developments including FDA decisions, peer-reviewed study publications, and partnership announcements. Our curated news collection helps stakeholders monitor progress in ENT-focused drug-device combinations and chronic disease management innovations.
Find verified updates on XHANCE clinical trials, financial earnings reports, and market expansion strategies. All content undergoes strict editorial review to ensure accuracy and relevance for investment research and therapeutic advancement tracking.
Bookmark this page for timely updates on Optinose's novel approaches to nasal drug delivery and specialty pharmaceutical developments. Regularly refreshed content supports informed decision-making for investors and healthcare analysts alike.
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on ENT and allergy patients, announced the granting of non-qualified stock option awards for 54,000 shares to three new employees on April 17, 2023. The stock options, granted outside of the 2010 Stock Incentive Plan, are in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at $2.05, matching the closing stock price on the grant date. The options have a 10-year term and will vest over four years, with one-fourth vesting on the first anniversary and the rest in monthly installments, contingent on continued service with the company.
Optinose (NASDAQ:OPTN) has announced that its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 17, 2023, at 3:45 p.m. ET. Interested parties can tune in to the live webcast through the Investors page of the Optinose website. A replay of the presentation will be accessible for 30 days post-event.
Optinose specializes in providing treatments for patients attended to by ear, nose, and throat (ENT) and allergy specialists. The company aims to address specific needs within this domain. For further details, visit www.optinose.com or follow them on social media platforms such as Twitter and LinkedIn.
Optinose (NASDAQ:OPTN) reported net revenues of $20.9 million for Q4 2022, down 7% from the previous year, and $76.3 million for the full year, marking a 4% increase. The decline in Q4 revenues is attributed to fewer prescriptions for XHANCE. The company recently submitted an sNDA to the FDA for a new indication of XHANCE as a treatment for chronic rhinosinusitis, expecting a decision by May 2023. For 2023, Optinose forecasts total revenues from XHANCE to be $62 million to $68 million, with reductions in operating expenses by approximately $30 million.
Optinose (NASDAQ:OPTN) announced that it will report its fourth quarter 2022 financial results and corporate updates on March 7, 2023, before market open. The company, which focuses on patients treated by ENT and allergy specialists, will host a conference call at 8:00 a.m. Eastern Time on the same day. Participants can access the call via a webcast on the company’s website or join by telephone after prior registration. A replay of the event will be available for 60 days following its conclusion.
